MannKind's Upcoming Catalyst(s)

MannKind's Afrezza faces an advisory committee meeting. If approved, the inhaled insulin will have to compete with injected versions made by Eli Lilly and Novo Nordisk.

Mar 27, 2014 at 10:35PM

MannKind (NASDAQ:MNKD) faces an advisory committee meeting on Tuesday that will make a recommendation about whether the FDA should approve its inhaled insulin drug Afrezza.

But investors will get a sneak peek of what the FDA is thinking when the agency releases documents for the committee on Friday. Since the FDA has the final say -- it occasionally goes against the panel's recommendation -- the documents could be a big clue as to whether Afrezza is approved.

If Afrezza is approved, MannKind will face more catalysts, including signing a marketing partner to sell the drug and how well the launch proceeds.

Afrezza will compete with rapid-acting, injected insulins from Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). The inhaled version is arguably a better drug because it's both more convenient and causes fewer incidences of low blood sugar levels, but MannKind and its market partner (if it managed to find one) face an uphill battle to lure patients away from Eli Lilly's Humalog and Novo Nordisk's Novolog, which doctors have prescribed for years.

Watch the video below for more thought on the upcoming catalyst from Fool contributor Brian Orelli and health-care bureau chief Max Macaluso.

MannKind might have a great 2014, but our Chief Investment Officer likes this company
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Brian OrelliMax Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information